Unveiling new features of the human pathogen through the reconstruction and exploitation of a dedicated genome-scale metabolic model.

is notorious for causing severe pulmonary and central nervous system infections, particularly in immunocompromised patients. High mortality rates, associated with its tropism and adaptation to the brain microenvironment and its drug resistance profile, make this pathogen a public health threat and a World Health Organization (WHO) priority. This study presents the first reconstructed genome-scale metabolic model (GSMM), iRV890, for , which comprises 890 genes, 2598 reactions, and 2047 metabolites across four compartments.

Reconstruction and exploitation of a dedicated Genome-Scale Metabolic Model of the human pathogen .

is notorious for causing severe pulmonary and central nervous system infections, particularly in immunocompromised patients. High mortality rates, associated with its tropism and adaptation to the brain microenvironment and its drug resistance profile, makes this pathogen a public health threat and a World Health Organization (WHO) priority. In this study, we reconstructed GSMM iRV890 for , providing a promising platform for the comprehensive understanding of the unique metabolic features of , and subsequently shedding light on its complex tropism for the brain microenvironment and potentially informing the discovery of new drug targets.

Metabolic reconstruction of the human pathogen Candida auris: using a cross-species approach for drug target prediction.

Candida auris is an emerging human pathogen, associated with antifungal drug resistance and hospital candidiasis outbreaks. In this work, we present iRV973, the first reconstructed Genome-scale metabolic model (GSMM) for C. auris.

YEASTRACT+: a portal for the exploitation of global transcription regulation and metabolic model data in yeast biotechnology and pathogenesis.

YEASTRACT+ (http://yeastract-plus.org/) is a tool for the analysis, prediction and modelling of transcription regulatory data at the gene and genomic levels in yeasts. It incorporates three integrated databases: YEASTRACT (http://yeastract-plus.

A Genome-Scale Metabolic Model for the Human Pathogen and Early Identification of Putative Novel Antifungal Drug Targets.

is an emerging human pathogen whose incidence is rising worldwide, while an increasing number of clinical isolates display resistance to first-line antifungals, demanding alternative therapeutics. Genome-Scale Metabolic Models (GSMMs) have emerged as a powerful in silico tool for understanding pathogenesis due to their systems view of metabolism, but also to their drug target predictive capacity. This study presents the construction of the first validated GSMM for -iDC1003-comprising 1003 genes, 1804 reactions, and 1278 metabolites across four compartments and an intercompartment.